Knight Therapeutics Inc.
Knight Therapeutics Inc., a prominent Canadian biopharmaceutical company, is headquartered in Montreal, Quebec. Founded in 2014, Knight Therapeutics focuses on the acquisition, development, and commercialisation of innovative pharmaceutical products, primarily in the areas of oncology, infectious diseases, and rare diseases. With a commitment to addressing unmet medical needs, the company has established a strong market position through strategic partnerships and a robust pipeline of unique therapies. Knight Therapeutics is recognised for its dedication to patient-centric solutions, offering a range of products that stand out for their efficacy and safety profiles. As a leader in the biopharmaceutical industry, Knight Therapeutics continues to make significant strides in improving health outcomes across Canada and beyond.
DitchCarbon Score
How does Knight Therapeutics Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Knight Therapeutics Inc.'s score of 25 is lower than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Knight Therapeutics Inc.'s reported carbon emissions
Knight Therapeutics Inc., headquartered in Canada, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. As of now, Knight Therapeutics Inc. does not inherit emissions data from any parent or related organizations, and there are no commitments to industry-standard initiatives such as the Science Based Targets initiative (SBTi) or the Carbon Disclosure Project (CDP). In the context of climate commitments, it is essential for companies in the pharmaceutical sector to establish clear emissions reduction strategies and transparency in reporting to align with global climate goals. However, without specific data or commitments, Knight Therapeutics Inc. remains unquantified in its climate impact and initiatives.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Knight Therapeutics Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
